Drug Monograph

Drug/Drug Class: **Lyrica CR® (pregabalin) extended release tablet /Fibromyalgia**
Prepared for: MO HealthNet
Prepared by: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Lyrica CR® is available in an extended-release tablet containing 82.5 mg, 165 mg, or 330 mg pregabalin respectively.
Manufacturer:	Parke-Davis, Division of Pfizer Inc., NY, NY 10017.
Indications:	Lyrica CR® is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. Efficacy of Lyrica CR® has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.
Costs:	$12.77 per tablet of each strength of Lyrica CR®. Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☒ Non-Preferred ☐ Appropriate Indications ☐ No PA Required

Prepared By: Luke Boehmer PharmD
Date: May 9, 2018